ClinicalTrials.Veeva

Menu
S

San Marcus Research Clinic | Miami Lakes, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BMS-986165
Cenerimod
KarXT
Cenicriviroc
TAK-279
PF-06865571
KPL-404
Vancomycin
MD-7246
Rezpeg

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 28 total trials
Locations recently updated

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Enrolling
Moderate to Severe Atopic Dermatitis
Drug: Rezpegaldesleukin
Drug: Placebo

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to sever...

Enrolling
Lupus Erythematosus, Systemic
Drug: Cenerimod
Drug: Placebo

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Enrolling
Plaque Psoriasis
Drug: Placebo
Drug: TAK-279

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequ...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo

This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Al...

Enrolling
Psychosis Associated With Alzheimer's Disease
Drug: Placebo
Drug: KarXT

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Placebo
Drug: Povorcitinib

This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.

Active, not recruiting
Rheumatoid Arthritis
Drug: Tc99m tilmanocept

The purpose of this research is to evaluate the primary objectives of safety and efficacy (rate of clinical cure) of 2 dosages of CRS3123 (200 mg and...

Active, not recruiting
Clostridioides Difficile Infection
Drug: CRS3123
Drug: Active Comparator

The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis a...

Active, not recruiting
Atopic Dermatitis
Psoriasis
Biological: Placebo
Biological: XmAb27564

The purpose of the study is to compare the efficacy, safety, tolerability, and immunogenicity of ADL-018 compared to XOLAIR in patients with Urticari...

Enrolling
Chronic Idiopathic Urticaria
Drug: Xolair Prefilled Syringe
Drug: Omalizumab Injection

This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: HM15211
Drug: Placebo of HM15211

The MOOD study will evaluate the safety and efficacy of a noninvasive, self-administered external Combined Occipital and Trigeminal Neurostimulation...

Active, not recruiting
MDD
Device: Relivion®DP- Sham
Device: Relivion®DP- Active

Trial sponsors

Bristol-Myers Squibb (BMS) logo
Idorsia Pharmaceuticals logo
Incyte logo
Karuna Therapeutics logo
Pfizer logo
C
Enanta Pharmaceuticals logo
Exact Sciences Corporation logo
Hanmi Pharmaceutical logo
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems